Plus Therapeutics Inc. Granted Continued Nasdaq Listing Amid Compliance Efforts; Must Meet Equity and Stock Price Requirements by September 2025
Plus Therapeutics Inc. has been granted continued listing on Nasdaq after appealing a potential delisting due to a stockholders’ equity deficit of $23.6 million. The company must meet a minimum equity requirement of $2.5 million by August 14, 2025, and achieve a closing bid price of at least $1.00 per share for 10 consecutive business days by September 8, 2025, to maintain compliance.
Plus Therapeutics Inc. is facing potential delisting from Nasdaq due to non-compliance with the requirement to maintain a minimum of $2.5 million in stockholders’ equity. As of March 31, 2025, the company reported a stockholders’ equity deficit of $23,641,000. After appealing the initial decision, the company was granted a reprieve by a Hearings Panel on July 22, 2025. Plus Therapeutics Inc. must demonstrate compliance with the equity requirement by August 14, 2025, through a public disclosure detailing transactions undertaken to meet the requirement and ensuring long-term compliance. Additionally, the company must achieve a closing bid price of at least $1.00 per share for 10 consecutive business days by September 8, 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-179382), on August 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
